A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Glucagon-Like Peptide-2 (GLP-2) is a hormone produced ... particularly those related to metabolism and intestinal function. It is known for its ability to enhance nutrient absorption, particularly ...